GlassScriptPhysician profile
Susan Jane Gawalt
NPI 1548294853
$321.68
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $35.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $97.83 | 2019 | |
| Pfizer INC. | $56.28 | 2019-2020 | |
| Cranial Technologies, INC | $54.13 | 2019-2020 | |
| Kaleo, INC. | $51.47 | 2019 | |
| Shire North American Group INC | $21.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.86 | 2019 | |
| Merck Sharp & Dohme LLC | $12.05 | 2019 | |
| Tris Pharma INC | $11.52 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Gawalt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.